Company: BLTE
Filing Date: 2025-01-27
Form Type: 424B7
Source: 0001104659-25-006367
Chunk: 19

Company: BELITE BIO, INC
Filing Date: 2025-01-27
Form: 424B7
Chunk 19
---
 the power to dispose or direct the disposition of ordinary shares. For purposes of this table, ordinary shares includes the identified selling shareholder’s Selling Shareholder Warrants in our company as if such Selling Shareholder Warrants were exercised to purchase ordinary shares of our company on a one for one basis. (2) The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the “Master Fund”), and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC (“Armistice Capital”), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. The Selling Shareholder Warrants are subject to a beneficial ownership limitation of 9.99%, which such limitation restricts the selling shareholder from exercising that portion of the Selling Shareholder Warrants that would result in the selling shareholder and its affiliates owning, after exercise, a number of ordinary shares in excess of the beneficial ownership limitation. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022. (3) Assumes that the identified selling shareholder sells all of the ordinary shares offered by it hereunder and does not acquire any additional ordinary shares (or securities convertible into or redeemable or exchangeable for ordinary shares) during the offering. We cannot advise you as to whether the selling shareholder will in fact sell any or all of its ordinary shares. In addition, the selling shareholder may sell, transfer or otherwise dispose of, at any time and from time to time, the ordinary shares in transactions exempt from the registration requirements of the Securities Act after the date for which the information set forth in the table above is provided.

S-13

TABLE OF CONTENTS

### USE OF PROCEEDS
We will not receive any of the proceeds from sales of offered shares by the selling shareholder. We have agreed to pay all costs and expenses incurred in connection with the registration under the Securities Act of the offered shares being registered hereby, other than the fees and disbursements of counsel retain by us in relation to the preparation of this prospectus supplement, which shall be paid by the selling shareholder. The proceeds from any sales are solely for the account of the selling shareholder.

<div align='center'>S-14</div>

TABLE OF CONTENTS

### PLAN OF DISTRIBUTION
The selling shareholder is selling up to an aggregate of 651,